Biotron (BIT) has provided an exciting update on its BIT225 compound, a possible cure for HIV, by confirming it enhances the immune response to the deadly virusThe compound is the first of its kind to both inhibit HIV and increase immune response to the virus, allowing it to be recognised and destroyedThe new data confirming BIT225's effectiveness against HIV will be presented at this weeks International AIDS conferenceShares in Biotron have increased following the announcement, trading up 20 per cent at 12 cents per share
BIT Price at posting:
9.5¢ Sentiment: Buy Disclosure: Held
